1. Varga J, Denton CP, Wigley FM. Scleroderma.
New York: Springer, 2012: 361-371; 373-395.
2. Dinser R, Frerix M, Meier FM, Klingel K, Rolf
A. Endocardial and myocardial involvement in
systemic sclerosis--is there a relevant
inflammatory component? Joint Bone Spine
2013; 80: 320-323.
3. Allanore Y, Avouac J, Kahan A. Systemic
sclerosis: an update in 2008. Joint Bone Spine
2008; 75: 650-655.
4. Ferri C, Emdin M, Nielsen H, Bruhlmann P.
Assessment of heart involvement.
ClinExpRheumatol 2003; 21: S24-S28.
5. Kahan A, Allanore Y. Primary myocardial
involvement in systemic sclerosis.
Rheumatology (Oxford) 2006; 45 Suppl 4: iv14-
iv17.
6. Steen VD, Medsger TA. Severe organ
involvement in systemic sclerosis with diffuse
scleroderma. Arthritis Rheum 2000; 43: 2437-
2444.
7. McLaughlin VV, Archer SL, Badesch DB, Barst
RJ, Farber HW, Lindner JR, Mathier MA,
McGoon MD, Park MH, Rosenson RS, Rubin
LJ, Tapson VF, Varga J. ACCF/AHA 2009
expert consensus document on pulmonary
hypertension a report of the American College
of Cardiology Foundation Task Force on Expert
Consensus Documents and the American Heart
Association developed in collaboration with the
American College of Chest Physicians;
American Thoracic Society, Inc.; and the
Pulmonary Hypertension Association. J Am
CollCardiol 2009; 53: 1573-1619.
8. Condliffe R, Kiely DG, Peacock AJ, Corris PA,
Gibbs JS, Vrapi F, Das C, Elliot CA, Johnson
M, DeSoyza J, Torpy C, Goldsmith K, Hodgkins
D, Hughes RJ, Pepke-Zaba J, Coghlan JG.
Connective tissue disease-associated pulmonary
arterial hypertension in the modern treatment
era. Am J RespirCrit Care Med 2009; 179: 151-
157 .
9. Proudman SM, Stevens WM, Sahhar J,
Celermajer D. Pulmonary arterial hypertension
in systemic sclerosis: the need for early
detection and treatment. Intern Med J 2007; 37:
485-494.
10. Silver RM, Medsger Jr TA, Bolster MB.
Systemic sclerosis and scleroderma variants:
clinical aspects. In: Koopman WJ. Arthritis and
allied conditions. 15th ed. Philadelphia:
Lippincot Williams & Wilkins, 2005: 1633-
1680
11. Lambova S, Müller-Ladner U. Pulmonary
arterial hypertension in systemic sclerosis.
Autoimmun Rev 2010; 9: 761-770.
12. Saito M1, Wright L1,2, Negishi K1, Dwyer
N3, Marwick TH1,2. Mechanics and prognostic
value of left and right ventriculardysfunction in
patients with systemic sclerosis. Eur Heart J
Cardiovasc Imaging. 2018 Jun 1;19(6):660-667.
13. Dedeoglu R1, Adroviç A2, Oztunç F3, Sahin
S2, Barut K2, Kasapcopur O2. New Insights
into Cardiac Involvement in
Juvenile Scleroderma: A Three-Dimensional
Echocardiographic Assessment Unveils
Subclinical Ventricle Dysfunction.
PediatrCardiol. 2017 Dec;38(8):1686-1695.
14. Zlatanovic M1, Tadic M2, Celic V2,3, Ivanovic
B3,4, Stevanovic A2, Damjanov N5,3. Cardiac
mechanics and heart rate variability in patients with systemicsclerosis: the association that we
should not miss. Rheumatol Int. 2017
Jan;37(1):49-57.
15. Vemulapalli S1, Cohen L2, Hsu V3. Prevalence
and risk factors for left ventricular diastolic
dysfunction in a scleroderma cohort. Scand J
Rheumatol. 2017 Jul;46(4):281-287.
16. Karna SK1, Rohit MK2, Wanchu A3. Right
ventricular thickness as predictor of global
myocardial performance in systemic sclerosis: A
Doppler tissue imaging study.
Indian Heart J. 2015 Nov-Dec;67(6):521-8.
17. Meune C1, Khanna D2, Aboulhosn J3, Avouac
J4, Kahan A5, Furst DE3, Allanore Y5.
A right ventricular diastolic impairment is
common in systemicsclerosis and is associated
with other target-organ damage. Semin Arthritis
Rheum. 2016 Feb;45(4):439-45.